Rocky Mountain Cannabis Research Center

落基山大麻研究中心

• 批准号: 10709326
• 负责人: KENT E. HUTCHISON
• 金额: $ 277.36万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10709326
• 关键词: Acute; Adolescence; Adult; Affect; Behavior; Behavioral; Biological; Biological Assay; Biological Markers; Blood; Blood specimen; Cannabidiol; Cannabinoids; Cannabis; Centers of Research Excellence; Communities; Data; Data Analyses; Data Collection; Data Set; District of Columbia; Dose; Elderly; Endocannabinoids; Epidiolex; Foundations; Funding; Future; Goals; Health; Hemp; Industry; Knowledge; Laboratories; Legal; Legal Status; Lipids; Longevity; Machine Learning; Measures; Mediating; Medical Marijuana; Modeling; Moods; Neurocognition; Neurocognitive; North America; Outcome; Participant; Pharmacologic Substance; Pharmacology; Pharmacy facility; Pilot Projects; Placebos; Public Health; Randomized; Recreation; Research; Research Project Grants; Resources; Risk; Sampling; Scientist; Self Administration; Structure; System; Terpenes; Tetrahydrocannabinol; Time; United States; United States National Institutes of Health; age group; behavior measurement; behavioral outcome; data cleaning; data harmonization; data sharing; design; emerging adult; endogenous cannabinoid system; experience; innovation; lipid mediator; middle age; novel; repository; response; success; user-friendly; web based interface

PROJECT SUMMARY/ABSTRACT ROCKY MOUNTAIN CANNABIS RESEARCH CENTER (RM-CRC) The United States has recently experienced enormous changes in the legal status and public acceptance of cannabis. Recreational and medical cannabis products that contain varying amounts of tetrahydrocannabinol (THC) and cannabidiol (CBD) are now widely available throughout North America. Despite these changes, research on the effects of THC and CBD has been lacking. The central goals of this Research Center of Excellence application are to evaluate, in three research projects that span emerging, middle-aged, and older adults, how CBD affects the use of and subjective response to THC, and whether these effects are mediated by the endocannabinoid system (ECS) and associated lipids. To that end, the three research projects within the RM-CRC utilize research strategies that capitalize on three key innovations. First, the projects will employ mobile pharmacology laboratories to collect biological samples and assess the acute effects of THC and CBD on key neurocognitive and behavioral outcomes, endocannabinoids, and other lipids that interact with the ECS. Second, under the auspices of an FDA IND we hold for hemp-derived CBD, projects will randomly assign participants to CBD or placebo and will parametrically manipulate either the dose of CBD or whether the CBD product contains THC, to determine how hemp-derived CBD products may impact the effects of THC. Finally, the projects rely on newly designed assays within our Cannabis Research Analytics Core (CRAC) to measure cannabinoids, metabolites, terpenes, endocannabinoids, and other lipid mediators in blood samples. The Data Harmonization and Analysis Core (DHAC) will deploy a single-solution system to support data collection, harmonization across projects, and sharing of the data with the larger scientific community directly and via NIH approved repositories. The DHAC will also harmonize previously collected data (from 7 R01s, n=1359) and conduct advanced machine learning analyses of the relationships between THC and CBD blood levels, endocannabinoids and other lipid mediators, and behavioral data. The results will inform center-wide analyses of the harmonized P50 project data. Thus, the CRAC and DHAC provide the RM-CRC with significant added value that will allow the Center to generate significant new knowledge with respect to how changes in the ECS and related lipids mediate the effects of THC and CBD across the lifespan. The RM-CRC is expected to be a significant resource to the field more broadly by providing other scientists access to data regarding CBD effects on psychiatric and health outcomes, cannabinoid, metabolite, and terpene blood levels, and 100+ endocannabinoids and related lipid mediators in approximately 2000 participants.

项目摘要/摘要 落基山大麻研究中心(RM-CRC) 美国最近在法律地位和公众接受度方面经历了巨大的变化 大麻。含有不同量四氢大麻酚的娱乐和医用大麻产品 四氢呋喃(THC)和大麻二酚(CBD)现在北美各地都能买到。尽管有这些变化， 关于THC和CBD的影响一直缺乏研究。这个研究中心的中心目标是 优秀申请将在三个研究项目中进行评估，这三个项目涵盖了新兴、中年和老年 成人，CBD如何影响THC的使用和主观反应，以及这些影响是否通过 内源性大麻素系统(ECS)和相关的脂类。为此，该中心的三个研究项目 RM-CRC利用研究战略，利用三项关键创新。首先，这些项目将使用移动电话 药理实验室收集生物样本并评估THC和CBD对关键疾病的急性影响 神经认知和行为结果、内源性大麻素和其他与ECS相互作用的脂质。第二, 在我们为大麻衍生的CBD举办的FDA IND的赞助下，项目将随机分配参与者到 CBD或安慰剂，并将参数控制CBD的剂量或CBD产品是否包含 THC，以确定大麻衍生CBD产品可能如何影响THC的效果。最后，这些项目依赖于 我们的大麻研究分析核心(CRAC)内新设计的分析方法可以测量大麻类化合物， 血液样本中的代谢物、萜类、内源性大麻素和其他脂质介体。数据的协调 分析核心(DHAC)将部署单一解决方案系统，以支持数据收集、协调 项目，并与更大的科学界直接和通过NIH批准的储存库共享数据。 DHAC还将协调以前收集数据(来自7个R01，n=1359)，并进行先进的机器 THC与CBD血药浓度、内源性大麻素等血脂关系的学习分析 调解人和行为数据。结果将成为对统一的P50项目数据进行全中心分析的依据。 因此，CRAC和DHAC为RM-CRC提供了重要的附加值，使中心能够 产生关于ECS和相关脂类的变化如何调节 THC和CBD对寿命的影响。预计RM-CRC将成为外地的重要资源 更广泛地说，通过向其他科学家提供关于CBD对精神和健康影响的数据 结果，大麻素、代谢物和萜类血液水平，以及100+内源性大麻素和相关脂质 调解员约有2000人参加。